BioLineRx 2026年第二季度财报及管线进展电话会议纪要

发布时间：2026-08-31 一、AI总结内容 一、核心业务与管线进展 1. Glixone管线：针对胶质母细胞瘤（GBM），为口服双靶点口服小分子，可激活TENT2酶、修复DNA损伤，血脑屏障穿透性佳；临床前数据显示在多种GBM模型（含替莫唑胺耐药患者来源异种移植模型）中肿瘤生长抑制与生存期获益显著，抗瘤效果优于现有标准疗法，将于2026年ESMO等会议发布卵巢癌相关协同数据；一期临床试验正在开展，2026年7月已启动二期扩展试验，预计2027年上半年公布一期数据。 2. 胰腺癌（PDAC）管线：合作项目中，6个月随访期内联合特瑞普利单抗、标准化疗的试验入组进度符合计划，预设的无效性分析预计2026年底开展。 3. Airmed商业化产品：2026年第二季度销售额160万美元，为公司带来30万美元版税收入。 二、财务状况 1. 2026年二季度：总收入因Glixone里程碑较上年同期增加60万美元；研发费用约900万美元，较上年同期增加70万美元，主要因Glixone项目相关支出，剔除该项目后费用略降；非运营支出约70万美元，上年同期为190万美元，均为境外负债公允价值调整；净亏损430万美元，上年同期为350万美元。 2. 现金流：截至2026年6月30日，现金及等价物1310万美元，预计可支撑至2027年上半年；2026年7月完成375万美元定向增发，资金已到账。三、关键风险与后续关注 1. Glixone临床进展、PDAC试验结果、Airmed产品商业化进度存在不确定性，可能影响公司业绩。 2. 后续将关注Glixone二期试验数据、卵巢癌协同疗法开发、PDAC试验无效性分析结果。 二、音频原文（转写） Of GlixOne and GVM across multiple in vivo studies, including a Temazolamide resistant patient derived xenobreth model. In three orthotopic cellderived xenograft or CDX GVM models, GlixOne produced significant tumor growth inhibition and survival benefit across all doses tested, with greater benefit at higher dose levels. Notably, wewere we also completed the subcutaneous Temazolamide resistant patient derived xenograft or PBXG. In that model, GLIX1 demonstrated a robust anti-tumor effect, while Gmosolamide, the currentstandard of care chemotherapy, showed no effect.These results further support GLIX1's potential to treat a broad range of patients with GPM, including those that do not respond to Gmosolamide. These results will also be presented at the ENO 2026 and SNOW 2026 conferences. In July, we announced highly encouraging new preclinical. 那个。 Demonstrating strong synergy between licks. Andthe department. elaborate It appears. arrived atthe. Rapid. Model of age or purpose. Cancer. Astanding report. Market impetus. have historically shown limited efficacy 是。 The study included six arms. 嗯。Platinum. Swim out of there. Again, a elaborate amount of. 你这。Isyour expected optimal. どうします？As well as a low dose glix one arm, a low dose glix one elaborate cup. nation arm. and. 说话。 The low dose clicks will elaborate. Accommodation. Substantially better application. See. Than the control arm and. Versus either molecule. Model pair. Despite using lower doses. 死笔给。 combination. The combination also achieved. reduction. Comparable design. flat. 是。这个。Thank you.Therapy bit. Sure. In the setting. these resultsreinforce genetic lethality I mean, licks, woodand parapet hippers. important はい。 to include an ovarian. Yes, well. In the phase two expansion part. Looking ahead, we look forward to presenting our data on LynxOne and PARP inhibitor synergy across HR proficient ovarian cancer lines as well as the PBX model at the ESMO annual conference in Madrid this October, where the abstract has been Given these data on synergy,we have also commenced initial discussions withseveral leading developers of PARVINIMETERS regarding potential collaborations leveraging GLIXOM. As we have said before, but if there is repeating, the unmet need of glioblastoma remains sig nificant. It is the most common and aggressive form of primary brain cancer occurring at all ages but peaking in patients in their fifties and sixties when incidents increasing alongside an aging global population. The current standard of care was established more than twenty years ago with only limited improvement since median survival following diagnosis remains approximately twelve to eighteen months by twenty thirty annual GVM incidents. Thank you. To reach over eighteenthousand patients in the US. 嘘。 and over thirteen thousand Across. The eu four.我呢？Representing a. Buying total addressable market. Point seven billion dollars in the US and Europe. Hold on. We continue to view this as a. open. with few competitors. 是。 We remain very encouraged. Purged by the progress of the glitz program. was. Both in the class.I think. Expanding. this is. It was. Look forward to. Keeping you apprised of our progress. Progress as we advance this development. 对对对。 Across a range of people. Answer so. Turning nowto pancreatic cancer or pdac. All that we weredoing. Rice. Help. 自分。Try to be. Yeah. Of the year. OUTLIKING. We continue to support its ongoing. development in the Columbia University is important. both who generated Bye, bye. is executing a random. Optimize these two. Ah, worthwhile.有人。 Chemo for men. We are pleased to report. that. Enrollment continues to track well. This trial isevaluating what six of four tied in combinationwith the P1 inhibitor Simbilimab and standard chemotherapies, gem cytamine and napaclexaxel. Asnoted previously, a pre-specified interim futility analysis is planned for when forty percent of progressive free survival events are observed and expected later this year. I'd now like to briefly touch on effects of this performance. TheAirman team continues to make progress driving Infectant adoption, generating sales of one pointsix million dollars in the second quarter of twenty twenty six, which resulted in the zero point three mil